Exelixis: Mid-Cap Oncology Concern Continues To Deliver Growth [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
Exelixis: Mid-Cap Oncology Concern Continues To Deliver Growth Summary Today, we revisit fast-growing mid-cap oncology concern Exelixis which recently posted Q2 results. Sales are a third higher than a year ago, and the company has a huge cash balance, but the stock is where it was a year ago. We examine key highlights of earnings results and what is on the horizon for the firm in the paragraphs below. As for literary criticism in general: I have long felt that any reviewer who expresses rage and loathing for a novel or a play or a poem is preposterous. He or she is like a person who has put on full armor and attacked a hot fudge sundae or a banana split Over the next week, we will be checking in on several small and midcap biotech concerns that have recently posted Q2 results. We will highlight key takeaways from earnings results, recent analyst commentary, the current state of the company's balance sheet, upcoming potential catalysts, and our updated view on the firm's prospects. To
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Global Colorectal Cancer Pipeline Insights Report for 2024: An In-Depth Analysis of Clinical and Nonclinical Developments [Yahoo! Finance]Yahoo! Finance
- Pheochromocytoma Pipeline Insight Report 2024, Featuring Genentech, Exelixis, Advanced Accelerator Applications, Enterome, FUJIFILM Toyama Chemical, Ipsen, Pfizer and Astex Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]Yahoo! Finance
- Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024Business Wire
- Global Liver Cancer Drug Market Size To Worth USD 7.6 Billion By 2033 | CAGR Of 10.90% [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 2/6/24 - Beat
EXEL
Sec Filings
- 4/18/24 - Form ARS
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form DEF
- EXEL's page on the SEC website